Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a significant discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This disconnect is particularly notable given the sector's robust fundamentals and innovation pipeline, which suggest a potential for meaningful rerating.
The key drivers of this opportunity include:
- Undervalued and Under-owned Sector: Healthcare is trading at approximately 17 times forward earnings, compared to 21 times for the S&P 500. This discount is well below the long-term average, making it an attractive entry point for investors.
- Political Headwinds Abating: Political uncertainties, such as the US drug-pricing agreement under the Trump administration, have largely been resolved. This removes a significant overhang that had deterred new capital from entering the sector.
- Accelerating M&A Activity: Biopharma mergers and acquisitions (M&A) are gaining momentum, with large pharma companies holding substantial financial firepower to address patent cliffs. This activity is expected to drive growth and innovation in the sector.
- Innovation in Medtech: New technologies, from robotic surgery to continuous glucose monitoring, are creating new blockbuster markets with durable growth profiles. AI is emerging as a cost and efficiency lever, rather than a disruptive threat.
- Defensive Qualities: Healthcare is a defensive sector, providing a stable investment option during periods of market volatility. This is particularly relevant in the current market environment, where technology and AI stocks are attracting significant capital.
Despite the sector's underperformance in the past two years, driven by political uncertainty and rising interest rates, the fundamentals remain strong. The resolution of the most-favored-nation pricing dispute with the US government has stabilized the sector, and small and mid-cap biotech names have performed well on the back of strong clinical results and acquisition activity.
Healthcare providers, particularly US health insurance companies, have also shown signs of improvement in the first quarter of 2026, with medical costs being absorbed by high premiums. Medtech, however, remains under pressure due to uncertainty around the Affordable Care Act subsidies.
The valuation case for healthcare is compelling, with the MSCI World Healthcare Index trading at a discount to the broader market. Medtech, in particular, is trading at a lower multiple despite strong organic revenue and earnings growth. This dislocation presents an opportunity for investors to build healthcare exposure at attractive levels.
Innovation is the key to long-term growth in the healthcare sector. New products and treatment modalities, such as lipoprotein(a) therapy and advanced medtech solutions, are creating new revenue pools. AI is being used as an efficiency tool rather than a disruptor, with potential savings in drug development and automation in healthcare operations.
M&A activity is a structural imperative for big pharma, given the looming patent expirations. The sector's large pharma companies have substantial financial firepower to drive M&A, which is expected to accelerate and create value.
For wealth managers and family office professionals, healthcare is an increasingly logical complement to concentrated technology positions. The sector's defensive qualities and innovation-driven growth make it an attractive option for diversification. As one multi-family office representative noted, healthcare is one of the best sectors for the current generation due to its domain expertise.
Bellevue Asset Management, a specialist in healthcare equities, positions itself as a partner for investors seeking differentiated healthcare exposure. With a focus on publicly listed healthcare, medtech, and emerging markets healthcare, the firm believes that the current dislocation represents a window of opportunity that disciplined allocators should not ignore.
